Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia

February 26, 2025 updated by: Pierre Fabre Dermo Cosmetique

Multi-omics Approaches and Biometrological Analyses to Better Understand Androgenetic Alopecia: Exploratory Study

Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness.

Although it has been shown that testosterone metabolism plays a central role in this pathology, targeting this biological pathway is not fully efficient to treat androgenetic alopecia, suggesting that other factors are involved, notably factors linked to the perifollicular environment. Moreover, the very specific pattern of androgenetic alopecia is not yet fully understood: the occipital and lower temporal areas of the scalp are always preserved. Once the hair follicle has disappeared, it is not possible to make it grow back, it is then important to provide a treatment that slows down the progression of androgenetic alopecia at the earliest stage of the pathology, and that specifically targets the affected area.

The aim of this study is to better understand androgenetic alopecia pathophysiology by a multi-omic approaches and biometrological analysis, in the same study, on the local ecosystem of bald scalp areas and non-bald scalp areas of adult with androgenetic alopecia, compared to scalp of adult without androgenetic alopecia.

Study Overview

Study Type

Interventional

Enrollment (Actual)

46

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Toulouse, France, 31100
        • Skin Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Selection criteria:

Criteria related to the population:

  • Male
  • Subject aged between 30 and 50 years included

Criteria related to the scalp condition:

  • Subject with hair length over 3 cm
  • Subject presenting a negative pull test result

Specific for non-AGA group:

• Non-alopecic men with full head of hair with uniform scalp coverage (homogeneous hair density on the vertex, occiput, left and right parietal areas)

Specific for AGA group:

• Androgenetic alopecic men with progressive AGA for more than 5 years: stage between III to IV included according to the Hamilton's classification modified by Norwood

Non-selection criteria:

Criteria related to the population:

  • Subject having received on study areas artificial UV exposure, excessive or prolonged exposure to natural sunlight within 2 months before the selection visit
  • Subjects with frizzy hair

Criteria related to diseases:

  • Subject having neoplastic disease (history of disease or disease on-going)
  • Subject having severe acute progressive disease (infectious syndromes, inflammatory, COVID-19, acute fever...) occurred within the last 3 months before the selection visit liable to interfere with the study assessments
  • Subject with iron deficiency on-going, not treated or treated for less than 3 months before the selection visit
  • Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the investigator hazardous for the subject or incompatible with the study requirements

Specific for non-AGA group:

  • Subject with any type of alopecia
  • Subject with family history of androgenetic alopecia in the father with stage ≥ III according to the Hamilton's classification modified by Norwood

Specific for AGA group:

• Subject with non-androgenetic alopecia (Cicatricial alopecia, Alopecia aerata...)

Criteria related to procedures, treatments, products and/or hair care routine:

  • Radiotherapy, chemotherapy
  • Scalp surgery
  • Systematic or local androgenetic alopecia treatment or product, taken or applied for more than 4 consecutive weeks during the last 6 months before the selection visit
  • Any following hair care within the last 3 months before the selection visit: dyeing, bleaching, perm
  • Systemic or local non-steroidal anti-inflammatory drug taken or applied on the scalp for more than 1 week during the last month (systematic NSAIDs) or 2 weeks (local NSAIDs) before the selection visit

Non-inclusion criteria:

Criteria related to the population:

  • Subject having received on study areas artificial UV exposure, excessive or prolonged exposure to natural sunlight between selection and inclusion visit

Criteria related to the disease:

• Subject with any adverse event occurring between selection and inclusion visit liable to interfere with the study assessments

Criteria related to treatments and/or products:

• Any procedures, treatments, products and/or hair care taken, applied or performed between selection and inclusion visit liable to interfere with the study assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Control subject group
Measurements will be taken from the scalp: on the vertex and occiput areas.
Samples will be taken from the scalp: on the vertex and occiput areas.
Other: Subject group with androgenetic alopecia
Measurements will be taken from the scalp: on the vertex and occiput areas.
Samples will be taken from the scalp: on the vertex and occiput areas.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cutaneous pH measurement
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Sebum quantification : by Lipidic Index (LI) - Sebumeter®
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Skin elasticity : by determination of the mechanical property of the skin with a biomechanical device
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Cutaneous hydratation : by Hydratation Index (IH) - DermaLab®
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Cutaneous barrier integrity : by Trans-Epidermal Water Loss (TEWL) - Vapometer®
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Lipidomic profile by mass spectroscopy (in-vivo measurements)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Lipidomic profile by sampling method (absorbent paper)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Microbiota analysis by sampling method (hair follicles)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Microbiota analysis by sampling method (swabs)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Metabolite analysis by sampling method (hair follicles)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Transcriptomic analysis by sampling method (hair follicles)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Transcriptomic analysis by sampling method (swabs)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)
Lipidomic profiles by sampling method (swabs)
Time Frame: baseline (Visit 1- Day 1)
baseline (Visit 1- Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 5, 2024

Primary Completion (Actual)

April 25, 2024

Study Completion (Actual)

April 25, 2024

Study Registration Dates

First Submitted

February 21, 2025

First Submitted That Met QC Criteria

February 26, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 26, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • INTERALOPECIE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Biometrological measurements

Subscribe